Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
For comprehensive long-term safety data, see our detailed long-term safety analysis
One fascinating aspect of BPC-157 dosing is the wide effective range observed in animal studies
The main semaglutide formulation for weight loss is Wegovy, which is approved for chronic weight management
First month results in clinical trials showed an average weight loss of approximately 3.8 percent of baseline body weight at the 2.4 mg dose, but most researchers are still at 0.25 mg during this period
Obes Sci Pract 10(1):e706 Jensen AB et al (2023) Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study
Why Researchers Are Interested in BPC-157 Preclinical studies (primarily in rodent models) have examined BPC-157s influence on angiogenesis the formation of new blood vessels in damaged tissue contexts Research has investigated its interaction with the nitric oxide (NO) system and potential signaling effects on growth hormone receptors Gastrointestinal research has explored BPC-157s apparent cytoprotective properties in gastric and intestinal lining tissue Tendon and ligament research models have used BPC-157 to examine extracellular matrix signaling under injury conditions No human clinical trials have been completed as of 2025 all available data is from in-vitro and animal model research 2
